Royalty Report: Drugs, Therapeutic, Pharmaceuticals – Collection: 29294

$150.00

Curated Royalty Rate Report
Created On: 2020-07-15, Record Count: 6

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Created On: 2020-07-15
Record Count: 6

Primary Industries

  • Drugs
  • Therapeutic
  • Pharmaceuticals
  • Disease
  • Cancer
  • Delivery
  • Medical

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 29294

License Grant
The Company granted the development partners exclusive licenses to use the Geomatrix technology in products throughout the world.
License Property
A significant part of the Company's business is developing applications of its Geomatrix(TM) technologies. Geomatrix is a range of technologies by which drugs taken orally in tablet form are formulated so as to control the amount, timing and location of the release of the drug in the body. The Company focuses its research and development efforts on the reformulation of existing drugs using its technologies rather than the discovery of new chemical compounds.
Field of Use
Xatral 10mg OD is a once per day Zero Order Geomatrix formulation of Alfuzosin used for the treatment of the functional symptoms of benign prostatic hyperplasia (BPH), a common disorder in men over the age of 50.

IPSCIO Record ID: 29425

License Grant
Licensor announced an amended agreement with respect to Paxil CR (paroxetine).
License Property
Paxil CR, a controlled release version of the much prescribed drug prescribed for central nervous system disorders.  Paxil CR is a modified release version of Paxil/Seroxat (paroxetine) using a combination of the Positioned Release and Zero Order Geomatrix systems.  
Paxil CRâ„¢ is a modified release version of Paxil/Seroxat (paroxetine HCL) which uses a combination of the Positioned Release and Zero Order Geomatrixâ„¢ systems. Paxil is an FDA-approved drug that is currently marketed primarily in the United States and Europe and is an immediate release formulation prescribed for central nervous system disorders.
Field of Use
Geomatrixâ„¢ is a range of technologies by which drugs taken orally in tablet form are formulated so as to control the amount, timing and location of the release of the drug in the body.

IPSCIO Record ID: 26466

License Grant
Under the terms of collaborative agreement in 1988, the Licensee bores all of the costs of research and development according to a budget agreed by the Company and Licensee.  In return, the Company granted Licensee an exclusive license to market Dilacor XR throughout the world.
License Property
Dilacor XR is a once per day Zero Order Geomatrix formulation of diltiazem hydrochloride, a calcium channel blocking agent indicated for hypertension and for the management of chronic stable angina.  Geomatrix technologies can improve the efficacy of orally administered drugs and enhance compliance by patients with prescribed medical treatments by permitting the drug to be taken less frequently, by reducing side effects and by causing the drug to be released at more specific locations within the body.  The Geomatrix technologies use hydrophillicmethylcellulose, or HPMC, matrices which govern the release profile of a drug depending on the viscosity of HPMC used and the rate of surface area exposure.  The 'release profile' refers to the rates at which a drug tablet releases the active drug component over the period of time after the drug is taken.
Field of Use
The rights granted apply to medical treatments by using drugs.

IPSCIO Record ID: 7340

License Grant
The Canadian Licensor entered into an exclusive License Agreement with the Japanese Licensee pursuant to which the Licensee was granted the right to develop and commercialize PRX302 in Japan for the treatment of the symptoms of BPH, prostate cancer, prostatitis or other diseases of the prostate.
License Property
The Licensor is currently developing PRX302 as a treatment for the symptoms of benign prostatic hyperplasia, or BPH, commonly referred to as an enlarged prostate. PRX302 is designed to be a convenient treatment that is safer and less invasive than surgery and more effective and better tolerated than currently approved pharmaceutical therapies.

IPSCIO Record ID: 7324

License Grant
In this related party cross-license agreement the Company granted an exclusive license to use the Company’s technology for certain applications.

In return, the Licensee granted the Company an exclusive license to use Licensee's technology for certain applications.

License Property
TUNA® (transurethral needle ablation) system treats benign prostatic hyperplasia (BPH), a non-cancerous condition also known as “enlarged prostate.”

The TUNA System is designed to offer a minimally invasive alternative for the treatment of benign prostatic hyperplasia by selectively shrinking the hyperplastic tissue that compresses the urethra limiting urinary flow.

IPSCIO Record ID: 27477

License Grant
Licensor granted right to technology used in development in a new version of Paxil.
License Property
Paxil CR is a controlled release version of the much prescribed drug prescribed for central nervous system disorders.

Paxil CR is a modified release version of Paxil/Seroxat (paroxetine) using a combination of the Positioned Release and Zero Order Geomatrix systems.  Paxil is an FDA-approved (February 1999) drug that is currently marketed primarily in the United States and Europe.   In early 2001 an approvable letter from the FDA was received for a second CR indication, panic disorder.   A third CR indication, pre-menstrual dysphoric disorder, a severe form of pre-menstrual syndrome is being developed.  In  April, 2002, the product was launched in the U.S.  Note that in May 2005, they renegotiated this license and the upper range of the royalty payment was increased.

Field of Use
The rights granted apply to the healthcare industry.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.